Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives $3.33 Consensus Target Price from Analysts

Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) have been given an average recommendation of “Hold” by the five research firms that are presently covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $3.33.

SYRS has been the topic of a number of research reports. JMP Securities reaffirmed a “market perform” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. TD Cowen reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Brookline Capital Management reissued a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price objective (down previously from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Finally, StockNews.com initiated coverage on Syros Pharmaceuticals in a research report on Friday, January 24th. They set a “sell” rating for the company.

Insiders Place Their Bets

In related news, Director Nancy A. Simonian sold 134,713 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $0.27, for a total value of $36,372.51. Following the transaction, the director now directly owns 41,070 shares in the company, valued at $11,088.90. This trade represents a 76.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 12.26% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Syros Pharmaceuticals

An institutional investor recently bought a new position in Syros Pharmaceuticals stock. GSA Capital Partners LLP bought a new stake in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 15,905 shares of the company’s stock, valued at approximately $34,000. GSA Capital Partners LLP owned about 0.06% of Syros Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Stock Down 2.8 %

Shares of SYRS stock opened at $0.19 on Monday. Syros Pharmaceuticals has a twelve month low of $0.18 and a twelve month high of $7.96. The business has a fifty day simple moving average of $0.23 and a 200 day simple moving average of $1.87. The company has a market cap of $5.12 million, a P/E ratio of -0.06 and a beta of 1.31.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same quarter in the prior year, the business earned ($1.35) EPS. As a group, equities research analysts anticipate that Syros Pharmaceuticals will post -2.94 earnings per share for the current fiscal year.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.